Navigation Links
China Medical Technologies Reports Second Fiscal Quarter Financial Results
Date:11/18/2011

marketing expenses were RMB30.0 million (US$4.7 million) for 2Q FY2011, representing a 41.0% year-over-year increase. The year-over-year increases were primarily due to the increase in direct sales efforts for molecular diagnostic systems and sales incentives to direct sales personnel.

General and administrative expenses were RMB21.9 million (US$3.4 million) for 2Q FY2011, representing a 12.7% year-over-year decrease. The year-over-year decrease was primarily due to a decrease in stock compensation expense. Non-GAAP general and administrative expenses were RMB17.2 million (US$2.7 million) for 2Q FY2011, representing a 0.4% year-over-year decrease.

Interest expense on convertible notes was RMB32.7 million (US$5.1 million) for 2Q FY2011. Non-GAAP interest expense on convertible notes was RMB31.8 million (US$5.0 million) for 2Q FY2011. As of September 30, 2011, the Company had outstanding convertible notes of US$16.7 million in principal value which bore interest at 3.5% and matured in November 2011, and US$246.5 million and US$150.0 million in principal value of outstanding convertible notes which bear interest at 4% and 6.25% per annum, respectively, and matured or will mature in August 2013 and December 2016, respectively.

Interest expense related to amortization of convertible notes issuance costs was RMB3.9 million (US$0.6 million) for 2Q FY2011.

Interest expense related to amortization of share lending costs was RMB2.3 million (US$0.4 million) for 2Q FY2011.

Other income was RMB1.2 million (US$0.2 million) for 2Q FY2011.

Income tax expense was RMB29.4 million (US$4.6 million) for 2Q FY2011. The consistently high effective tax rate was due to the fact that certain expenses of the Company such as stock compensation expense, amortization of acquired intangible assets and interest expense of convertible notes were not deductible for income tax purpose. In addition, the Company accrues for withholding income tax on distributa
'/>"/>

SOURCE China Medical Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014  Beamz Interactive, Inc. (OTCQB: BZIC), ... today announced that it has signed an agreement ... supplier of innovative prosthetic, orthotic and assistive technology ... the agreement, RSL Steeper will promote and supply ... for use within UK residential care facilities through ...
(Date:12/17/2014)... MARLBOROUGH, Mass. , Dec. 17, 2014 /PRNewswire/ ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today announced completion of enrollment in ... results from the 3-month observations confirmed the 1-month ... year:  Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "MEMS Gyroscopes Analog Devices ... report to their offering. ... for tactical grade applications made a lot of ... of reliability. They are now accepted in high-reliability ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2
... 04, 2007 /PRNewswire-FirstCall/ --,Bionovo, Inc.'s lead drug ... the treatment of hot flashes associated with ... in the company's,double-blind, placebo- controlled, randomized Phase ... moderate to severe hot flashes,per week were ...
... analyses of progression-free survival in,the SPARC Phase ... risk of disease progression for patients receiving,satraplatin. ... well as presence or absence of pain., ... and GPC Biotech AG today announced the ...
Cached Medicine Technology:Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 2Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 3Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 4Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7
(Date:12/19/2014)... This is a professional and in-depth study on ... a focus on the Chinese market. The report provides ... manufacturers and is a valuable source of guidance and ... , Firstly, the report provides a basic overview of ... Then, the report explores the international and Chinese major ...
(Date:12/19/2014)... THURSDAY, Dec. 18, 2014 (HealthDay News) -- A new ... -- moderate to severe hot flashes and night sweats ... bones. Hot flashes are common during menopause, affecting ... menopause also affect women after menopause, since they then ... "Our findings suggest women who exhibit moderate or ...
(Date:12/19/2014)... Dec. 18, 2014 (HealthDay News) -- Traveling through the ... measles virus to three others within a four-hour time ... a new report shows. "The exposures in this ... rather than an international terminal, highlighting the fact that ... Jared Vega, an infectious disease specialist at the U.S. ...
(Date:12/17/2014)... Dr. Myo Nwe is the co-author of a ... Future” and co-founder of the Ace Medical Weight Loss Center ... a broad look at the industry of weight loss, and ... On film and in television shows, however, she says the ... aspects and played for basic laughs, which she believes impacts ...
(Date:12/17/2014)... 2014 A group of 127 scientists sent ... in reaction to a recent statement by the center that ... and derogated the efficacy of all brain exercises. , Signatories ... parts of the center’s statement critical of brain exercise companies ... also overstated its case, in a document it had entitled ...
Breaking Medicine News(10 mins):Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 4Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 5Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 6Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4
... group of commonly used cholesterol-lowering drugs, used by ... an anti-arrhythmic effect. Scientists with ... (definite) committee evaluated about 458 sudden cardiac deaths ... effect of Statin therapy. Among these about, 229 ...
... who have suffered from hardships early in their life become ... that they in reality become more gullible as they grow ... the finding of a new study by the University of ... troubled upbringing during childhood did not end up getting tough ...
... avian flu among migratory birds and many cases recorded in ... ministry of China reported a total of 399 bar-headed geese ... outbreaks in Tibet's Naqu district and the Guoluo Tibetan Autonomous ... outbreaks had occurred in separate locations, linked by the same ...
... A new study suggests that people preparing for surgery needs ... who warmed up by playing video games// like ‘Super Monkey ... were faster and made fewer errors than those who did ... a medical training course that included video games and was ...
... information circulating around donor-conceived children. A recent advertising campaign ... about their origin. Health authorities were flooded with inquiries ... 50 calls and emails from parents of donor-conceived children, ... who is the chief executive said that the sperm ...
... Pharmaceuticals and Chemicals Ltd today said it will ... Inc for 74.5 million dollars. // ... 100 per cent stake in CarboGen and Amcis--Solutia ... statement., ,The acquisition includes other assets used ...
Cached Medicine News:
... (PxE) is a licensed 96 well PCR machine, ... for money thermal cycling. It is built ... in manufacturing and retains a high level of ... products in the range. The combination of ...
Custom programming of 3 hot blocks and 1 cold block, 30% reduction in cycling time, Unmatched well-to-well uniformity, No gradient feature...
... With Exceptional Performance The sleek ... might be the first things ... is designed for performance. With ... premium, its small footprint is ...
... The 96-Well GeneAmp PCR System 9700 ... and Aluminum Sample Blocks Modules. The aluminum ... of PCR reactions and cycle sequencing in ... This allows the 96-well 9700 system to ...
Medicine Products: